It appears that your browser has cookies disabled.
The website requires your browser to enable cookies in order to login.
Please enable cookies and reload this page.
The presence of both TOP2A amplification and deletion in advanced cancer are associated with decreased survival, and occur frequently and concurrently with ERBB2 gene amplification (commonly refered to as HER2). The TOP2A (17q21) / ERBB2 (17q12) / SE 17 probe is designed as a triple-color assay to detect amplification at 17q12 as well as amplifications or deletions at 17q21. The chromosome 17 satellite enumeration probe (SE 17) at D17Z1 in blue is included to facilitate chromosome identification/enumeration.
Järvinen et al, 1999, Genes Chromosomes Cancer 26; 142-150.
Järvinen et al, 2000, Am. J. Pathology 156; 639-647.